Feb 2017 – Present · 9 yrs 2 mos

• General Manager Merck Biopharma France & Managing Director of Merck s.a., Merck Santé s.a.s., and Merck Serono s.a.s.

Oct 2013 – Jan 2017 · 3 yrs 3 mos

• Main Responsibilities: Responsible of Manufacturing and Supply for all Pharmaceuticals and Biologicals therapies. Oversee a team of 4500 colleagues located in 16 locations around the globe (5 biotech manufacturing sites, 2 Biotech development sites, 9 Pharmaceutical sites for small molecules). Manage production costs (OPEX) of 1.2 Bn€ and investment CAPEX of 250 Mio€.
• Strategy developer, established and implement a “supply centric” strategy for manufacturing and supply function articulated around 4 pillars (reliability, flexibility, scalability, regionalisation) and re-built a comprehensive production system across the entire plant network
• Game changer, turn around the function in less than two years, stop long series of supply crisis and lost sales, increased service level up to 99.9% for biotech and 98% for Pharma, bring back manufacturing costs under control, change and re-engage leadership at all level, and initiated a culture change journey
• Cross business player, turn manufacturing and supply into a function that dialogue and engage with key customers (commercial, franchises/brand, R&D teams).
• Member of the Merck Serono Pharmaceutical Executive Committee (2013-2015)

Jan 2012 – Jan 2014 · 2 yrs · Geneva Area, Switzerland

• Game changer, convinced Merck KGaA board to change its “100% innovation – no biosimilar” strategy. This results in a bold strategic move to capture the biosimilar business opportunity with the creation of a dedicated and independent business unit reporting to CEO with ring fenced mid-term resources (80 - 100 m€ budget p.a.).
• Strategy implementer, set up a full fletch Business Unit; attract senior experts to the team (50 by end 2013). Break down the global strategy into regional ones (with special focus on Brazil/LATAM).
• Portfolio driver negotiate and sign a portfolio partnership with Dr Reddy’s (India) for oncology biosimilars. The deal includes risk sharing, technology transfer, co-development, and multiple commercial agreements (e.g. co-promotion, exclusive and co-exclusive territories). In parallel established own internal biosimilar research and source (in lisc.) other targeted molecules. Drive pipeline forward.
• Cross business player, work with established franchises to develop/adapt their strategy toward biosimilar threat.

Jan 2010 – Jun 2012 · 2 yrs 5 mos · Geneva Area, Switzerland

• Drive the Divisional strategy and the Annual Strategic Planning Process, ensure alignment across Business Units and functions, and monitor execution and risk/mitigation actions.
• Lead Cross Business strategic initiatives (e.g. efficiency program, re-organization, governance, biosimilars)
• Secretary of the Executive Management Board: Coordinate the activities of the Management Board
• Monitor the Company Performance with global Balance Score Cards: Lead process, ensure alignment with strategic initiatives and Business Units, Functions and Countries. Track performance and deviation.
• Support Merck Serono’s President: Provide ideas, food for thought, challenge proposals to help ideas maturation, provide feedback received from the organization, alert on potential blockages/issues/silo thinking. Bring R&D experience. Lead special projects for the President.

Jan 2007 – Jan 2010 · 3 yrs · Geneva Area, Switzerland

• Provide project management resources, support and training to all development project teams to ensure high quality, speed, and consistency
• Provide high qualified Project Managers (25+) to support the
• Global Product Teams in charge of developing the R&D
• pipeline.
• Establish a Project Management Office (15+) in charge of
• developing the appropriate methods, tools and information
• systems to support pipeline development.
• Ensure across projects the consolidation of key project
• metric (time, cost, quality) analyse deviation. Facilitate the
• portfolio review.
• Drive budgeting exercice for R&D development project and
• ensure analysis of deviation.
• Develop and deliver training for Global Product Teams.
• Coordinate benchmarking information collection and analysis.
• Member of the Product Development Commitee steering all the
• development programs
• Management of an international team of 40+ people

Oct 2003 – Jan 2007 · 3 yrs 3 mos

• Lead the Early Stage Global Project Team Leaders (GPTLs) – 8 GPTLs
• Provide pro-active management of development projects,
• highlighting issues and potential solutions
• Ensure that for each project a cross-functional product
• development strategy, is developed and translated into a cross-
• functional operational plan.
• Coordinate across projects day-to-day tradeoffs on
• priorities / operational decisions to implement operational
• plans, report progress/issues
• Generate basis for Project evaluation (risk/value
• evaluation, development of alternatives)
• Lead the Project Management (PM) Department (15 Project Managers)
• Develop and ensure implementation of Project
• Management processes and reporting tools
• Ensures that PM Dpt supports project teams with
• appropriate PM process, tools, techniques & expertise.
• Coordinator of the Portfolio Steering Committees

Jan 2002 – Sep 2003 · 1 yr 8 mos

• Responsible of a new anti diabetic drug co-developped in the US (Phase II) with a Japanese partner.
• Organisation and management of an international team of 30
• people, involving pre-clinical, clinical, marketing, regulatory, and
• operations representatives.
• Definition of all project strategies (clinical development plan,
• marketing plan). Project planning, resources (human, cash flow)
• and project value (patient benefit, NPV) management. Research
• of partner.
• Management of all matters concerning our relationship with a
• Japanese partner

May 1995 – Dec 2001 · 6 yrs 7 mos

• Definition and implementation of the Department strategy from
• early drug discovery to Life Cycle Management.Management of
• all operational activities.
• Member of the Development Steering committee. Advisor for the
• Generic Affiliate Company.
• Constant contributor in International Project Teams involving US
• and Japanese partners. Relationships with Health Authorities
• (EMEA, FDA; French Agency).
• Department of 12 employees (Scientists, Technicians),
• Good Laboratory Practice status.

Feb 1992 – Apr 1995 · 3 yrs 2 mos

• Management of clinical pharmacokinetic studies in healthy volunteers. Study, analysis and preparation of Investigator Brochure, CTX, NDA. Complete design and evaluation of modified release galenic forms.

Nov 1989 – Jan 1992 · 2 yrs 2 mos

• Management of a biopharmaceutical project co-developed with a Spanish Affiliate and supported by the European Community (EUREKA program). Implementation of the strategy, study monitoring and analysis, reporting to the sponsor (results, time, resources).